Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce (CELG-RI) Revenue
Annual & quarterly revenue history · segment & region breakdown
CELG-RI · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBristol-Myers Squibb Company Ce trailing twelve-month (TTM) revenue is $16.98B, an increase of 17.52% year-over-year from $15.28B in FY2018.
Revenue trend
2018 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2018-12-31 | $15.28B | +$2.28B | +17.52% |
| 2017-12-31 | $13.00B | +$1.77B | +15.80% |
| 2016-12-31 | $11.23B | +$1.97B | +21.32% |
| 2015-12-31 | $9.26B | +$1.59B | +20.67% |
| 2014-12-31 | $7.67B | +$1.18B | +18.12% |
| 2013-12-31 | $6.49B | +$0.99B | +17.93% |
| 2012-12-31 | $5.51B | +$0.66B | +13.73% |
| 2011-12-31 | $4.84B | +$1.22B | +33.55% |
| 2010-12-31 | $3.63B | +$0.94B | +34.79% |
| 2009-12-31 | $2.69B | +$0.44B | +19.30% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare CELG-RI revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Bristol-Myers Squibb Company Ce receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Bristol-Myers Squibb Company Ce reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Bristol-Myers Squibb Company Ce's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CELG-RI revenue · 4 questionsCELG-RI's trailing twelve-month (TTM) revenue is $16.98B. That is an increase of 17.52% year-over-year from $15.28B in FY2018.
▸ Source: FMP · Bristol-Myers Squibb Company Ce SEC filings · GAAP · Bristol-Myers Squibb Company Ce SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026